MHC affinity screening of genomically predicted neoantigen peptides identified the most immunogenic candidates, which activated CD4+ T cells, CD8+ T cells, and NK cells against colorectal cancer in vitro.
96.6% DC maturationwith optimally selected neoantigen peptides versus 0.051% in controls, demonstrating strong immune activation
What the researchers found
Neoantigens with MHC molecular affinity variation of 1-4 and HLA Type 1 association showed the highest immunogenicity, activating CD4+/CD8+ T cells and NK cells with 96.6% dendritic cell maturation versus 0.051% in controls.
Why it matters
Personalized cancer vaccines are one of the most promising cancer immunotherapy approaches, but identifying the right peptides is a bottleneck. This MHC affinity screening method could make neoantigen vaccine development faster and more reliable, bringing personalized cancer treatment closer to routine clinical use.
The numbers in context
9-amino-acid neoantigen peptides predicted from whole exome sequencing, screened through in vitro MHC class I molecular affinity simulation.
How the study worked
Whole exome sequencing of patient-derived colon cancer cells. In silico 9-amino-acid neoantigen prediction. In vitro dendritic cell-mediated antigen presentation to T cells. Immune response assessed by flow cytometry and ELISpot. MHC affinity variation and HLA typing correlated with immunogenicity.
Who was studied
Patient-derived colon cancer cells with neoantigen peptide screening
What this study cannot tell us
In vitro study — immune responses in a dish may not predict clinical vaccine efficacy. Patient-derived cells from a limited number of cases. The 14-day in vitro T cell expansion may not reflect in vivo kinetics. Manufacturing individual neoantigen vaccines remains complex and expensive.
How to read the evidence
Preliminary evidence: in vitro proof-of-concept demonstrating a screening methodology for neoantigen peptide selection. Clinical validation needed.
When this study was published
Published in 2024 in Frontiers in Immunology. Addresses a key bottleneck in personalized cancer vaccine development.
The bigger picture
Cancer vaccines using neoantigen peptides are in clinical trials at major cancer centers. The biggest challenge is efficient screening — most patients's tumors have hundreds of mutations, but only a few produce peptides that trigger strong immune responses. This MHC affinity-based screening approach could become a standard tool for selecting the most effective vaccine targets.
Questions still open
- Will neoantigen peptides selected by this MHC affinity method show superior clinical responses compared to other selection methods?
- Can this screening approach be automated for routine clinical use?
- How many neoantigens per patient need to be included in a vaccine for optimal immune response?
Common questions
What are neoantigen vaccines?
Why is selecting the right peptides important?
Read the original research
Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening.
Frontiers in immunology, 15, 1473145
Citation
Zhang, Siyu; Huang, Changxin; Li, Yongqiang; Li, Zhaoyang; Zhu, Ying; Yang, Lili; Hu, Haokun; Sun, Quan; Liu, Mengmeng; Cao, Songqiang. (2024). Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening.. Frontiers in immunology, 15, 1473145. https://doi.org/10.3389/fimmu.2024.1473145